Feltes, Timothy F <br/><br/>
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.  [electronic resource] 

 -  The Journal of pediatrics  Oct 2003 
 - 532-40 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0022-3476 
<br/><br/><label>Standard No.: </label>10.1067/s0022-3476(03)00454-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antiviral Agents--therapeutic use<br/>Comorbidity<br/>Double-Blind Method<br/>Heart Defects, Congenital--epidemiology<br/>Hospitalization--statistics & numerical data<br/>Humans<br/>Palivizumab<br/>Respiration, Artificial<br/>Respiratory Syncytial Virus Infections--epidemiology<br/>Risk Factors